TD Cowen Issues Positive Forecast for Cencora (NYSE:COR) Stock Price

Cencora (NYSE:COR) had its price target raised by investment analysts at TD Cowen from $350.00 to $400.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. TD Cowen’s price target would indicate a potential upside of 10.33% from the company’s previous close.

Several other analysts have also weighed in on COR. Wells Fargo & Company upped their price objective on Cencora from $337.00 to $354.00 and gave the company an “overweight” rating in a report on Wednesday, August 13th. UBS Group upped their price target on shares of Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a report on Friday. Evercore ISI set a $400.00 price objective on shares of Cencora and gave the company an “outperform” rating in a research report on Thursday. Robert W. Baird boosted their target price on shares of Cencora from $355.00 to $395.00 and gave the stock an “outperform” rating in a report on Thursday. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of Cencora in a research note on Thursday, October 30th. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $355.91.

Cencora Price Performance

Shares of COR stock traded up $1.85 during midday trading on Monday, reaching $362.55. 464,464 shares of the company were exchanged, compared to its average volume of 1,537,779. The company’s 50 day moving average price is $314.27 and its two-hundred day moving average price is $299.54. The company has a market cap of $70.29 billion, a P/E ratio of 37.28, a PEG ratio of 1.56 and a beta of 0.63. Cencora has a 12 month low of $223.92 and a 12 month high of $364.36. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The business had revenue of $83.73 billion for the quarter, compared to analyst estimates of $83.36 billion. During the same quarter last year, the business earned $3.34 earnings per share. The business’s revenue for the quarter was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, sell-side analysts expect that Cencora will post 15.37 earnings per share for the current year.

Insider Buying and Selling

In other Cencora news, Chairman Steven H. Collis sold 31,350 shares of the company’s stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total value of $9,087,111.00. Following the transaction, the chairman directly owned 305,913 shares of the company’s stock, valued at $88,671,942.18. This represents a 9.30% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Robert P. Mauch sold 5,097 shares of Cencora stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $326.80, for a total value of $1,665,699.60. Following the sale, the chief executive officer owned 37,940 shares of the company’s stock, valued at approximately $12,398,792. This represents a 11.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 41,544 shares of company stock valued at $12,230,941. Insiders own 10.80% of the company’s stock.

Institutional Trading of Cencora

A number of institutional investors have recently added to or reduced their stakes in the business. Atlantic Edge Private Wealth Management LLC increased its stake in shares of Cencora by 70.0% during the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after purchasing an additional 35 shares during the last quarter. Costello Asset Management INC bought a new stake in Cencora in the first quarter worth $28,000. Vermillion & White Wealth Management Group LLC raised its holdings in Cencora by 69.4% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock valued at $31,000 after buying an additional 43 shares in the last quarter. Cloud Capital Management LLC acquired a new stake in shares of Cencora in the third quarter worth about $31,000. Finally, Westside Investment Management Inc. boosted its stake in shares of Cencora by 200.0% during the 3rd quarter. Westside Investment Management Inc. now owns 105 shares of the company’s stock worth $33,000 after acquiring an additional 70 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.